The World Health Organization (WHO) has clear guidelines regarding the use of Ki67 index in defining the proliferative rate and assigning grade for pancreatic neuroendocrine tumor (NET). WHO mandates the quantification of Ki67 index by counting at least 500 positive tumor cells in a hotspot. Unfortunately, Ki67 antibody may stain both tumor and non-tumor cells as positive depending on the phase of the cell cycle. Likewise, the counter stain labels both tumor and non-tumor as negative. This non-specific nature of Ki67 stain and counter stain therefore hinders the exact quantification of Ki67 index. To address this problem, we present a deep learning method to automatically differentiate between NET and non-tumor regions based on images of Ki...
As the most lethal major cancer, pancreatic cancer is a global healthcare challenge. Personalized me...
Background: Proliferation markers, especially Ki67, are increasingly important in diagnosis and prog...
Pancreatic ductal adenocarcinoma (PDAC) mortality rates are projected to rise by 2030 due to factors...
Uncontrolled proliferation is a hallmark of cancer and can be assessed by labelling breast tissue us...
Ki-67 assessment is a key step in the diagnosis of neuroendocrine neoplasms (NENs) from all anatomic...
The Ki-67 index is an established prognostic factor in gastrointestinal neuroendocrine tumors (GI-NE...
Pancreatic cancer is a fatal malignancy with poor prognosis and limited treatment options. Early det...
Ki67 scoring is required for the grading of pancreatic neuroendocrine tumors. Ongoing debate exists ...
There is an unmet need for novel biomarkers to diagnose and monitor patients with neuroendocrine neo...
The Ki-67 proliferation index (PI) is a prognostic factor in neuroendocrine tumors (NETs) and define...
Pancreatic cancer is one of the global leading causes of cancer-related deaths. Despite the success ...
A common problem in the assessment of Ki67 proliferative index in well-differentiated gastrointestin...
Abstract: The grading system for pancreatic neuroendocrine tumors (PanNETs) adopted in 2010 by the W...
Background: The aim of this study is to demonstrate the feasibility of automatic classification of K...
We introduce a machine learning-based analysis to predict the immunohistochemical (IHC) labeling ind...
As the most lethal major cancer, pancreatic cancer is a global healthcare challenge. Personalized me...
Background: Proliferation markers, especially Ki67, are increasingly important in diagnosis and prog...
Pancreatic ductal adenocarcinoma (PDAC) mortality rates are projected to rise by 2030 due to factors...
Uncontrolled proliferation is a hallmark of cancer and can be assessed by labelling breast tissue us...
Ki-67 assessment is a key step in the diagnosis of neuroendocrine neoplasms (NENs) from all anatomic...
The Ki-67 index is an established prognostic factor in gastrointestinal neuroendocrine tumors (GI-NE...
Pancreatic cancer is a fatal malignancy with poor prognosis and limited treatment options. Early det...
Ki67 scoring is required for the grading of pancreatic neuroendocrine tumors. Ongoing debate exists ...
There is an unmet need for novel biomarkers to diagnose and monitor patients with neuroendocrine neo...
The Ki-67 proliferation index (PI) is a prognostic factor in neuroendocrine tumors (NETs) and define...
Pancreatic cancer is one of the global leading causes of cancer-related deaths. Despite the success ...
A common problem in the assessment of Ki67 proliferative index in well-differentiated gastrointestin...
Abstract: The grading system for pancreatic neuroendocrine tumors (PanNETs) adopted in 2010 by the W...
Background: The aim of this study is to demonstrate the feasibility of automatic classification of K...
We introduce a machine learning-based analysis to predict the immunohistochemical (IHC) labeling ind...
As the most lethal major cancer, pancreatic cancer is a global healthcare challenge. Personalized me...
Background: Proliferation markers, especially Ki67, are increasingly important in diagnosis and prog...
Pancreatic ductal adenocarcinoma (PDAC) mortality rates are projected to rise by 2030 due to factors...